Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novo Nordisk A/S (NVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 91,494,000
  • Shares Outstanding, K 2,550,000
  • Annual Sales, $ 16,611 M
  • Annual Income, $ 5,636 M
  • 36-Month Beta 0.72
  • Price/Sales 5.81
  • Price/Cash Flow 15.61
  • Price/Book 13.68

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.10 +8.40%
on 03/23/17
36.56 -1.86%
on 04/20/17
+2.20 (+6.53%)
since 03/21/17
3-Month
32.83 +9.29%
on 02/02/17
36.71 -2.26%
on 02/01/17
+0.35 (+0.99%)
since 01/20/17
52-Week
30.89 +16.15%
on 11/23/16
57.44 -37.53%
on 06/07/16
-20.95 (-36.86%)
since 04/21/16

Most Recent Stories

More News
Research and Markets - Global $2.47 Billion Acquired Hemophilia Treatment Market, 2023: Key Players are Baxalta, Novo Nordisk, Biogen, Pfizer & F. Hoffman La Roche

DUBLIN, Apr. 21, 2017 /PRNewswire/ --

NVO : 35.88 (-1.43%)
Research and Markets - Global $2.47 Billion Acquired Hemophilia Treatment Market, 2023: Key Players are Baxalta, Novo Nordisk, Biogen, Pfizer & F. Hoffman La Roche

Research and Markets has announced the addition of the "Global Acquired Hemophilia Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies...

NVO : 35.88 (-1.43%)
Watch for Novo Nordisk to Potentially Rebound After Falling 1.46% Yesterday

Novo Nordisk (NYSE:NVO) traded in a range yesterday that spanned from a low of $35.82 to a high of $36.29. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $35.98...

NVO : 35.88 (-1.43%)
Novo Nordisk A/S - Reduction of the share capital

Bagsvaerd, Denmark, 21 April 2017 - At Novo Nordisk's Annual General Meeting on 23 March 2017, it was decided to reduce the company's B share capital from DKK 402,512,800 to DKK 392,512,800 by cancellation...

NVO : 35.88 (-1.43%)
Global Diabetic Therapeutic Market 2017-2021: The Strong Potential of Biologics - Leading Players are AstraZeneca, Eli Lilly, Merck, Novo Nordisk & Sanofi - Research and Markets

Research and Markets has announced the addition of the "Global Diabetic Therapeutic Market 2017-2021" report to their offering.

NVO : 35.88 (-1.43%)
MRK : 61.89 (-1.06%)
LLY : 81.89 (-0.06%)
Veeva Global Commercial & Medical Summit to Feature Seven of the Top 10 Largest Pharmaceutical Companies and Leading Biotechs

Veeva Systems (NYSE: VEEV) will host the 2017 Veeva Global Commercial & Medical Summit, the largest commercial and medical affairs event in the life sciences industry, on May 7-9,...

NVO : 35.88 (-1.43%)
MRK : 61.89 (-1.06%)
VEEV : 51.83 (-1.28%)
APEJ Region to Record Fastest Sales of Safety Needles by 2027 End

VALLEY COTTAGE, New York, April 12, 2017 /PRNewswire/ --

NVO : 35.88 (-1.43%)
APEJ Region to Record Fastest Sales of Safety Needles by 2027 End

The sole purpose of designing safety needles was to avoid needlestick injuries while collecting fluids and delivering drugs to the body. The key players of global market for safety needles are enhancing...

NVO : 35.88 (-1.43%)
Merck's Bid to Add Cardiovascular Data on Januvia Label Fails

Merck announced that the FDA has denied approval to include cardiovascular outcomes data on the labels of its diabetes drug, Januvia (sitagliptin) and other medicines containing Januvia.

NVO : 35.88 (-1.43%)
JNJ : 121.76 (-0.09%)
MRK : 61.89 (-1.06%)
LLY : 81.89 (-0.06%)
Drug Makers Stocks Under Scanner -- Synergy Pharma, Novo Nordisk, Apricus Biosciences, and Sucampo Pharma

Stock-Callers.com has issued research reports on four Drug Manufacturers stocks, which are: Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Novo Nordisk A/S (NYSE: NVO), Apricus Biosciences Inc. (NASDAQ:...

SCMP : 9.45 (-3.08%)
NVO : 35.88 (-1.43%)
APRI : 1.20 (-12.41%)
SGYP : 4.11 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural...

See More

Support & Resistance

2nd Resistance Point 36.50
1st Resistance Point 36.19
Last Price 35.88
1st Support Level 35.67
2nd Support Level 35.46

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.